Advocacy Archives – Page 9 of 10 – Treatment Action Group

African Declaration to Eliminate Hepatitis C and Improve the Health of People Who Use Drugs

February 20, 2020
Dorrit Walsh

A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.

TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP

November 11, 2019
Dorrit Walsh

Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.

Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5

October 31, 2019
Dorrit Walsh

The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy

October 31, 2019
Dorrit Walsh

October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…

Activist Guide to Hepatitis C Virus Diagnostics

October 31, 2019
Chad Cipiti

The purpose of this new publication is to provide information for you and your community. The Activist Guide aims to provide a deeper focus on diagnosis with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.

Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson

October 31, 2019
Dorrit Walsh

Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.

Eight HIV/AIDS Research, Policy, and Advocacy Organizations File an Amici Curiae Brief in Staley v. Gilead – Background and Next Steps

October 30, 2019
Dorrit Walsh

On October 25, 2019, eight HIV/AIDS research, policy, and advocacy organizations filed an amicus brief in the U.S. District Court, in San Francisco, CA, in support of the plaintiffs in Staley v. Gilead.

Ensuring Community Leadership as Part of the Federal Ending the HIV Epidemic (EHE): A Plan for America

October 21, 2019
Dorrit Walsh

The ACT NOW: END AIDS (ANEA) coalition is seeking proposals for a new small grants program that aims to significantly increase local and state community leadership as part of the new federal Ending the HIV Epidemic (EHE): A Plan for America initiative.

Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics

October 31, 2017
Chad Cipiti

In July 2017, 37 treatment activists from 17 countries—including 14 low- and middle-income countries (LMICs)—met with representatives from three generics and three diagnostics companies. This Hepatitis C World Community Advisory Board meeting was an opportunity for activists to present demands…

Expanding the Use of the TB LAM Test for People with HIV

October 3, 2017
Dorrit Walsh

TAG and partners hosted this webinar on October 3, 2017. Speakers included Lynette Mabote, AIDS & Rights Alliance for Southern Africa; Lindiwe Mvusi, Department of Health, Republic of South Africa; Stephen Wanjala, MSF; and Wayne van Gemert, Global Drug Facility.…